$XBI $133.5 +0.6%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$RVVTF 3+.2% Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India. source
$INO +1.8% INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800. source
Pipeline Updates
$ACIU -10.5% On 6/2 AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta. source
$LYRA -4.6% Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis. source
$TMDX -0.7% TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021). source
$GKOS +2.3% Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt. source
$CTXR +0.8% Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial. source
$ANVS +7.7% Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study. source
$CCXI +2.1% ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress. source
$ARNA -0.3% Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO). source
$CRDF +3.9% Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer. source
$KDNY 5.2% Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress. source
$ORMP +1.8% Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study. source
$OTLK +1.2% Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial. source
$VBIV +14.5% VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM. source
$PDSB +18.7% PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting. source
$IFRX -3.5% InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab. source
$KNSA +3.3% Kiniksa Outlines Next Steps for the Development of Mavrilimumab. source
$ACRS -16.2% Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis. source
$RMTI +3.4% Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic® in Turkey. source
$AVXL +4.0% Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease. source
$FOLD +3.0% Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA. source
$AGEN +16.6% Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373. source
$HOOK -19.3% HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers. source
Financial Updates
$PCRX -1.4% Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021. source
$KNSA +3.3% Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis. source
$CYCN +30.2% On 6/4 Cyclerion Therapeutics Announces $18 Million Private Placement. source
$CYTR +26.0% CytRx to Present at Upcoming Investor Conferences: LD Micro Invitational XI Conference: June 8-10, 2021. source
$ACRS -16.2% Aclaris Announces Proposed Public Offering of Common Stock. source
Posted by FS